Skip to main content
NCBI home page
The Texas Heart Institute Journal logoLink to The Texas Heart Institute Journal
. 1990;17(4):330–336.

Aminoglycoside Therapy

Current and Prospective Uses

James E Leggett 1
PMCID: PMC324943  PMID: 15227525

Full text

PDF
330

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Appel G. B., Neu H. C. The nephrotoxicity of antimicrobial agents (second of three parts). N Engl J Med. 1977 Mar 31;296(13):722–728. doi: 10.1056/NEJM197703312961305. [DOI] [PubMed] [Google Scholar]
  2. Bartlett J. G., O'Keefe P., Tally F. P., Louie T. J., Gorbach S. L. Bacteriology of hospital-acquired pneumonia. Arch Intern Med. 1986 May;146(5):868–871. [PubMed] [Google Scholar]
  3. Bryan L. E., Kwan S. Aminoglycoside-resistant mutants of Pseudomonas aeruginosa deficient in cytochrome d, nitrite reductase, and aerobic transport. Antimicrob Agents Chemother. 1981 Jun;19(6):958–964. doi: 10.1128/aac.19.6.958. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bryan L. E., O'Hara K., Wong S. Lipopolysaccharide changes in impermeability-type aminoglycoside resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1984 Aug;26(2):250–255. doi: 10.1128/aac.26.2.250. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Craig W. A., Vogelman B. The postantibiotic effect. Ann Intern Med. 1987 Jun;106(6):900–902. doi: 10.7326/0003-4819-106-6-900. [DOI] [PubMed] [Google Scholar]
  6. Cudillo L., Masi M., Scimò M. T., Tribalto M., Cantonetti M., Criscuolo D., Papa G. Ceftriaxone plus amikacin in a single daily dose as empiric antibiotic therapy in granulocytopenic patients. J Chemother. 1989 Dec;1(6):413–416. doi: 10.1080/1120009x.1989.11738935. [DOI] [PubMed] [Google Scholar]
  7. Cunha B. A. Aminoglycosides: current role in antimicrobial therapy. Pharmacotherapy. 1988;8(6):334–350. doi: 10.1002/j.1875-9114.1988.tb04092.x. [DOI] [PubMed] [Google Scholar]
  8. Dee T. H., Kozin F. Gentamicin and tobramycin penetration into synovial fluid. Antimicrob Agents Chemother. 1977 Oct;12(4):548–549. doi: 10.1128/aac.12.4.548. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Delage G., Desautels L., Legault S., Lasalle R., Lapierre J. G., Lamarre A., Masson P., Spier S. Individualized aminoglycoside dosage regimens in patients with cystic fibrosis. Drug Intell Clin Pharm. 1988 May;22(5):386–389. doi: 10.1177/106002808802200504. [DOI] [PubMed] [Google Scholar]
  10. Fan S. T., Lau W. Y., Teoh-Chan C. H., Lau K. F., Mauracher E. H. Once daily administration of netilmicin compared with thrice daily, both in combination with metronidazole, in gangrenous and perforated appendicitis. J Antimicrob Chemother. 1988 Jul;22(1):69–74. doi: 10.1093/jac/22.1.69. [DOI] [PubMed] [Google Scholar]
  11. Fuhs D. W., Mann H. J., Kubajak C. A., Cerra F. B. Intrapatient variation of aminoglycoside pharmacokinetics in critically ill surgery patients. Clin Pharm. 1988 Mar;7(3):207–213. [PubMed] [Google Scholar]
  12. Gangadharam P. R., Perumal V. K., Podapati N. R., Kesavalu L., Iseman M. D. In vivo activity of amikacin alone or in combination with clofazimine or rifabutin or both against acute experimental Mycobacterium avium complex infections in beige mice. Antimicrob Agents Chemother. 1988 Sep;32(9):1400–1403. doi: 10.1128/aac.32.9.1400. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Hathorn J. W., Pizzo P. A. Is there a role for monotherapy with beta-lactam antibiotics in the initial empirical management of febrile neutropenic cancer patients? J Antimicrob Chemother. 1986 Mar;17 (Suppl A):41–54. doi: 10.1093/jac/17.suppl_a.41. [DOI] [PubMed] [Google Scholar]
  14. Hollender L. F., Bahnini J., De Manzini N., Lau W. Y., Fan S. T., Hermansyur K., Benny P., Husni A. N., Sutjipto, Lorber R. R. A multicentric study of netilmicin once daily versus thrice daily in patients with appendicitis and other intra-abdominal infections. J Antimicrob Chemother. 1989 May;23(5):773–783. doi: 10.1093/jac/23.5.773. [DOI] [PubMed] [Google Scholar]
  15. Hull J. H., Sarubbi F. A., Jr Gentamicin serum concentrations: pharmacokinetic predictions. Ann Intern Med. 1976 Aug;85(2):183–189. doi: 10.7326/0003-4819-85-2-183. [DOI] [PubMed] [Google Scholar]
  16. Kaloyanides G. J., Pastoriza-Munoz E. Aminoglycoside nephrotoxicity. Kidney Int. 1980 Nov;18(5):571–582. doi: 10.1038/ki.1980.175. [DOI] [PubMed] [Google Scholar]
  17. Karchmer A. W., Archer G. L., Dismukes W. E. Staphylococcus epidermidis causing prosthetic valve endocarditis: microbiologic and clinical observations as guides to therapy. Ann Intern Med. 1983 Apr;98(4):447–455. doi: 10.7326/0003-4819-98-4-447. [DOI] [PubMed] [Google Scholar]
  18. Korzeniowski O., Sande M. A. Combination antimicrobial therapy for Staphylococcus aureus endocarditis in patients addicted to parenteral drugs and in nonaddicts: A prospective study. Ann Intern Med. 1982 Oct;97(4):496–503. doi: 10.7326/0003-4819-97-4-496. [DOI] [PubMed] [Google Scholar]
  19. Lesar T. S., Rotschafer J. C., Strand L. M., Solem L. D., Zaske D. E. Gentamicin dosing errors with four commonly used nomograms. JAMA. 1982 Sep 10;248(10):1190–1193. [PubMed] [Google Scholar]
  20. Levy J., Smith A. L., Kenny M. A., Ramsey B., Schoenknecht F. D. Bioactivity of gentamicin in purulent sputum from patients with cystic fibrosis or bronchiectasis: comparison with activity in serum. J Infect Dis. 1983 Dec;148(6):1069–1076. doi: 10.1093/infdis/148.6.1069. [DOI] [PubMed] [Google Scholar]
  21. Lowy F. D., Chang D. S., Lash P. R. Synergy of combinations of vancomycin, gentamicin, and rifampin against methicillin-resistant, coagulase-negative staphylococci. Antimicrob Agents Chemother. 1983 Jun;23(6):932–934. doi: 10.1128/aac.23.6.932. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Maller R., Isaksson B., Nilsson L., Sörén L. A study of amikacin given once versus twice daily in serious infections. J Antimicrob Chemother. 1988 Jul;22(1):75–79. doi: 10.1093/jac/22.1.75. [DOI] [PubMed] [Google Scholar]
  23. Mann H. J., Fuhs D. W., Awang R., Ndemo F. A., Cerra F. B. Altered aminoglycoside pharmacokinetics in critically ill patients with sepsis. Clin Pharm. 1987 Feb;6(2):148–153. [PubMed] [Google Scholar]
  24. Martino P., Girmenia C., Raccah R., Micozzi A., Cimino G., Mandelli F. Ceftriaxone and amikacin as single daily dose in the empiric therapy for febrile episodes in neutropenic patients. Haematologica. 1990 Jan-Feb;75(1):69–74. [PubMed] [Google Scholar]
  25. Mattie H., Craig W. A., Pechère J. C. Determinants of efficacy and toxicity of aminoglycosides. J Antimicrob Chemother. 1989 Sep;24(3):281–293. doi: 10.1093/jac/24.3.281. [DOI] [PubMed] [Google Scholar]
  26. Mederski-Samoraj B. D., Murray B. E. High-level resistance to gentamicin in clinical isolates of enterococci. J Infect Dis. 1983 Apr;147(4):751–757. doi: 10.1093/infdis/147.4.751. [DOI] [PubMed] [Google Scholar]
  27. Mendelson J., Portnoy J., Sigman H. Pharmacology of gentamicin in the biliary tract of humans. Antimicrob Agents Chemother. 1973 Nov;4(5):538–541. doi: 10.1128/aac.4.5.538. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Meyer R. D. Risk factors and comparisons of clinical nephrotoxicity of aminoglycosides. Am J Med. 1986 Jun 30;80(6B):119–125. doi: 10.1016/0002-9343(86)90489-4. [DOI] [PubMed] [Google Scholar]
  29. Moellering R. C., Jr, Weinberg A. N. Studies on antibiotic syngerism against enterococci. II. Effect of various antibiotics on the uptake of 14 C-labeled streptomycin by enterococci. J Clin Invest. 1971 Dec;50(12):2580–2584. doi: 10.1172/JCI106758. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Moore R. D., Lietman P. S., Smith C. R. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis. 1987 Jan;155(1):93–99. doi: 10.1093/infdis/155.1.93. [DOI] [PubMed] [Google Scholar]
  31. Moore R. D., Smith C. R., Lietman P. S. The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia. J Infect Dis. 1984 Mar;149(3):443–448. doi: 10.1093/infdis/149.3.443. [DOI] [PubMed] [Google Scholar]
  32. Moore R. D., Smith C. R., Lipsky J. J., Mellits E. D., Lietman P. S. Risk factors for nephrotoxicity in patients treated with aminoglycosides. Ann Intern Med. 1984 Mar;100(3):352–357. doi: 10.7326/0003-4819-100-3-352. [DOI] [PubMed] [Google Scholar]
  33. Noone P., Parsons T. M., Pattison J. R., Slack R. C., Garfield-Davies D., Hughes K. Experience in monitoring gentamicin therapy during treatment of serious gram-negative sepsis. Br Med J. 1974 Mar 16;1(5906):477–481. doi: 10.1136/bmj.1.5906.477. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Nordström L., Ringberg H., Cronberg S., Tjernström O., Walder M. Does administration of an aminoglycoside in a single daily dose affect its efficacy and toxicity? J Antimicrob Chemother. 1990 Jan;25(1):159–173. doi: 10.1093/jac/25.1.159. [DOI] [PubMed] [Google Scholar]
  35. Pancoast S. J. Aminoglycoside antibiotics in clinical use. Med Clin North Am. 1988 May;72(3):581–612. doi: 10.1016/s0025-7125(16)30760-x. [DOI] [PubMed] [Google Scholar]
  36. Papapetropoulou M., Papavassiliou J., Legakis N. J. Effect of the pH and osmolality of urine on the antibacterial activity of gentamicin. J Antimicrob Chemother. 1983 Dec;12(6):571–575. doi: 10.1093/jac/12.6.571. [DOI] [PubMed] [Google Scholar]
  37. Paradelis A. G., Triantaphyllidis C. J., Mironidou M., Crassaris L. G., Karachalios D. N., Giala M. M. Interaction of aminoglycoside antibiotics and calcium channel blockers at the neuromuscular junctions. Methods Find Exp Clin Pharmacol. 1988 Nov;10(11):687–690. [PubMed] [Google Scholar]
  38. Pennington J. E. Penetration of antibiotics into respiratory secretions. Rev Infect Dis. 1981 Jan-Feb;3(1):67–73. doi: 10.1093/clinids/3.1.67. [DOI] [PubMed] [Google Scholar]
  39. Quinn J. P., Dudek E. J., DiVincenzo C. A., Lucks D. A., Lerner S. A. Emergence of resistance to imipenem during therapy for Pseudomonas aeruginosa infections. J Infect Dis. 1986 Aug;154(2):289–294. doi: 10.1093/infdis/154.2.289. [DOI] [PubMed] [Google Scholar]
  40. Regeur L., Colding H., Jensen H., Kampmann J. P. Pharmacokinetics of amikacin during hemodialysis and peritoneal dialysis. Antimicrob Agents Chemother. 1977 Feb;11(2):214–218. doi: 10.1128/aac.11.2.214. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Rotheram E. B., Jr Clinical response and peak concentrations of aminoglycosides. J Infect Dis. 1988 Feb;157(2):395–396. doi: 10.1093/infdis/157.2.395. [DOI] [PubMed] [Google Scholar]
  42. Shearer B. G., Legakis N. J. Pseudomonas aeruginosa: evidence for the involvement of lipopolysaccharide in determining outer membrane permeability to carbenicillin and gentamicin. J Infect Dis. 1985 Aug;152(2):351–355. doi: 10.1093/infdis/152.2.351. [DOI] [PubMed] [Google Scholar]
  43. Siegenthaler W. E., Bonetti A., Luthy R. Aminoglycoside antibiotics in infectious diseases. An overview. Am J Med. 1986 Jun 30;80(6B):2–14. doi: 10.1016/0002-9343(86)90473-0. [DOI] [PubMed] [Google Scholar]
  44. Sturm A. W. Netilmicin in the treatment of gram-negative bacteremia: single daily versus multiple daily dosage. J Infect Dis. 1989 May;159(5):931–937. doi: 10.1093/infdis/159.5.931. [DOI] [PubMed] [Google Scholar]
  45. Verpooten G. A., Giuliano R. A., Verbist L., Eestermans G., De Broe M. E. Once-daily dosing decreases renal accumulation of gentamicin and netilmicin. Clin Pharmacol Ther. 1989 Jan;45(1):22–27. doi: 10.1038/clpt.1989.4. [DOI] [PubMed] [Google Scholar]
  46. Vogelman B., Craig W. A. Kinetics of antimicrobial activity. J Pediatr. 1986 May;108(5 Pt 2):835–840. doi: 10.1016/s0022-3476(86)80754-5. [DOI] [PubMed] [Google Scholar]
  47. Vogelman B., Gudmundsson S., Turnidge J., Leggett J., Craig W. A. In vivo postantibiotic effect in a thigh infection in neutropenic mice. J Infect Dis. 1988 Feb;157(2):287–298. doi: 10.1093/infdis/157.2.287. [DOI] [PubMed] [Google Scholar]
  48. Walker J. M., Wise R., Mitchard M. The pharmacokinetics of amikacin and gentamicin in volunteers: a comparison of individual differences. J Antimicrob Chemother. 1979 Jan;5(1):95–99. doi: 10.1093/jac/5.1.95. [DOI] [PubMed] [Google Scholar]
  49. Wong G. A., Pierce T. H., Goldstein E., Hoeprich P. D. Penetration of antimicrobial agents into bronchial secretions. Am J Med. 1975 Aug;59(2):219–223. doi: 10.1016/0002-9343(75)90356-3. [DOI] [PubMed] [Google Scholar]
  50. Young L. S. Empirical antimicrobial therapy in the neutropenic host. N Engl J Med. 1986 Aug 28;315(9):580–581. doi: 10.1056/NEJM198608283150910. [DOI] [PubMed] [Google Scholar]
  51. de Vries P. J., Verkooyen R. P., Leguit P., Verbrugh H. A. Prospective randomized study of once-daily versus thrice-daily netilmicin regimens in patients with intraabdominal infections. Eur J Clin Microbiol Infect Dis. 1990 Mar;9(3):161–168. doi: 10.1007/BF01963832. [DOI] [PubMed] [Google Scholar]
  52. ter Braak E. W., de Vries P. J., Bouter K. P., van der Vegt S. G., Dorrestein G. C., Nortier J. W., van Dijk A., Verkooyen R. P., Verbrugh H. A. Once-daily dosing regimen for aminoglycoside plus beta-lactam combination therapy of serious bacterial infections: comparative trial with netilmicin plus ceftriaxone. Am J Med. 1990 Jul;89(1):58–66. doi: 10.1016/0002-9343(90)90099-y. [DOI] [PubMed] [Google Scholar]

Articles from Texas Heart Institute Journal are provided here courtesy of Texas Heart Institute

RESOURCES